carcinosarcoma (Cancer)
Information
- Disease name
- carcinosarcoma
- Disease ID
- DOID:4236
- Description
- "A mixed cell type cancer that has_material_basis_in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components." [url:http\://en.wikipedia.org/wiki/Mixed_M%C3%BCllerian_tumor, url:http\://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=44003&version=Patient&language=English, url:http\://www.cancer.gov/dictionary/?CdrID=44003]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04458597 | Active, not recruiting | N/A | Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. | August 26, 2020 | April 1, 2024 |
| NCT04681248 | Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | |||
| NCT03395080 | Completed | Phase 2 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | March 5, 2018 | January 27, 2021 |
| NCT00815945 | Completed | Phase 2 | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | June 2008 | January 2012 |
| NCT03241745 | Completed | Phase 2 | A Study of Nivolumab in Selected Uterine Cancer Patients | August 3, 2017 | April 1, 2024 |
| NCT04513665 | Completed | Phase 2 | ZW25 in Women With Endometrial Cancers | August 12, 2020 | March 8, 2024 |
| NCT05252416 | Recruiting | Phase 1/Phase 2 | (VELA) Study of BLU-222 in Advanced Solid Tumors | April 7, 2022 | September 30, 2026 |
| NCT04122872 | Recruiting | GISAR German Interdisciplinary Sarcoma Registry | November 29, 2018 | January 2038 | |
| NCT04688749 | Terminated | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage | July 17, 2019 | December 31, 2022 | |
| NCT05265793 | Unknown status | Phase 2 | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma | November 21, 2021 | June 30, 2023 |
| NCT03570437 | Unknown status | Phase 2 | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? | May 17, 2018 | June 30, 2023 |
| NCT03933761 | Withdrawn | Phase 2 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy | July 29, 2019 | August 2, 2021 |
- Disase is a (Disease Ontology)
- DOID:154
- Cross Reference ID (Disease Ontology)
- ICDO:8980/3
- Cross Reference ID (Disease Ontology)
- MESH:D002296
- Cross Reference ID (Disease Ontology)
- MESH:D018199
- Cross Reference ID (Disease Ontology)
- MESH:D018200
- Cross Reference ID (Disease Ontology)
- NCI:C34448
- Cross Reference ID (Disease Ontology)
- NCI:C3730
- Cross Reference ID (Disease Ontology)
- NCI:C8975
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:112684005
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:63264007
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:84427001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0007140
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206627
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1334603
- Exact Synonym (Disease Ontology)
- malignant mixed mesodermal (mullerian) tumor
- Exact Synonym (Disease Ontology)
- malignant mixed Mullerian tumor
- Exact Synonym (Disease Ontology)
- mesodermal mixed tumor
- Exact Synonym (Disease Ontology)
- mixed Mesodermal (mullerian) tumor
- Exact Synonym (Disease Ontology)
- MMMT
- Exact Synonym (Disease Ontology)
- mullerian mixed tumor
- MeSH unique ID (MeSH (Medical Subject Headings))
- D002296